Skip to main content
. 2018 Sep 29;10(10):365. doi: 10.3390/cancers10100365

Figure 3.

Figure 3

Viability of SKOV-3 and NGP-127 cells treated with different concentrations of target drugs: (A) Akt inhibitor Afuresertib; (B) EGFR and ErbB inhibitor Sapitinib; (C) phospholipase C inhibitor U73122; and (D) Notch inhibitor FLI-06. Viability and IC50 were measured with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) test.